Reversin 121

Reversin 121 is a small-molecule inhibitor that has garnered significant attention in biochemical research due to its potent ability to modulate multidrug resistance (MDR) mechanisms, particularly through interactions with ATP-binding cassette (ABC) transporters such as P-glycoprotein (P-gp, also known as MDR1 or ABCB1). Structurally distinct and functionally relevant, Reversin 121 is widely utilized as a tool compound for investigating the molecular underpinnings of drug efflux processes in cellular systems. Its role as a chemosensitizer and efflux pump modulator makes it a valuable resource for studies seeking to elucidate the dynamics of drug transport, cellular pharmacokinetics, and resistance mechanisms in various experimental models. The compound's specificity and efficacy have positioned it as a preferred choice for researchers aiming to dissect transporter-mediated drug interactions and to develop strategies for overcoming resistance in preclinical contexts.

Multidrug resistance research: Reversin 121 is extensively employed in the study of multidrug resistance phenomena, particularly in cancer cell lines that exhibit elevated P-glycoprotein activity. By selectively inhibiting the efflux function of ABC transporters, the compound enables researchers to assess the contribution of these proteins to resistance profiles. Its application aids in differentiating transporter-mediated effects from intrinsic cellular resistance, supporting the development of new approaches to circumvent MDR in vitro. The use of this inhibitor provides a robust experimental framework for probing the biochemical and genetic factors that drive resistance to chemotherapeutic agents and other xenobiotics.

Drug efflux pump characterization: As a potent modulator of ABC transporter activity, Reversin 121 serves as a reference compound for functional assays designed to quantify and characterize efflux pump dynamics. Researchers utilize it in flow cytometry, fluorescence-based accumulation assays, and transport studies to validate the activity of P-glycoprotein and related transporters. Its inclusion in experimental protocols facilitates the calibration of assay systems, benchmarking of transporter inhibitors, and comparative analyses of efflux activity across different cell types or experimental conditions. Such studies are critical for advancing knowledge of membrane transport mechanisms and for screening potential modulators with therapeutic relevance.

Pharmacokinetic interaction studies: The compound is a valuable tool for investigating drug-drug interactions mediated by efflux transporters at the cellular and tissue levels. By inhibiting P-glycoprotein, Reversin 121 allows researchers to assess how transporter activity influences the intracellular accumulation, retention, and distribution of co-administered compounds. These studies inform the prediction of pharmacokinetic profiles and potential interactions in preclinical models, contributing to the rational design of drug delivery strategies and the optimization of compound libraries for reduced transporter liability.

Chemosensitization assays: In preclinical research, Reversin 121 is frequently incorporated into chemosensitization protocols to evaluate the impact of efflux pump inhibition on the cytotoxicity of various agents. Its use enhances the sensitivity of resistant cell lines to structurally diverse compounds, enabling the assessment of synergistic effects and the identification of compounds whose efficacy is compromised by active efflux. These assays are instrumental in screening candidate molecules for susceptibility to transporter-mediated resistance and in validating the functional significance of efflux inhibition in modulating cellular responses.

Transporter substrate validation: Researchers rely on Reversin 121 as a control or comparator in substrate identification studies for ABC transporters. By inhibiting efflux activity, the compound helps delineate whether novel or existing molecules are substrates of P-glycoprotein or related transporters. Such validation is essential for drug discovery projects aiming to minimize undesirable transporter interactions, as well as for mechanistic investigations into substrate specificity, binding sites, and transporter conformational states. The ability to distinguish true substrates from non-interacting compounds underpins the development of safer and more effective research tools and probe molecules.

1. Zeta-potential-changing nanoparticles conjugated with cell-penetrating peptides for enhanced transfection efficiency

2. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

3. Implications of ligand-receptor binding kinetics on GLP-1R signalling

4. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

5. High fat diet and GLP-1 drugs induce pancreatic injury in mice